Ayrmid Expands Partnership with RoslinCT to Support Omisirge® Production
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2025
0mins
Source: Businesswire
- Strategic Partnership Expansion: Ayrmid Ltd. expands its strategic partnership with RoslinCT by signing a commercial supply agreement to support the production of Omisirge®, marking a significant advancement in the cell therapy sector.
- FDA Approval for New Indication: Omisirge® has received FDA approval for treating patients with severe aplastic anemia, broadening its patient population and expected to significantly enhance market demand and sales potential.
- Technology Transfer and Production Capacity: Under the agreement, RoslinCT will complete technology transfer and support commercial manufacturing at its cGMP cell therapy facility in Hopkinton, MA, ensuring long-term patient supply.
- Commitment to Innovative Therapies: This collaboration not only strengthens Ayrmid's dual sourcing strategy but also showcases RoslinCT's capability to support the scalable production of innovative therapies, further solidifying its leadership in the cell and gene therapy space.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like undefined with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
